Multicenter, Safety Study Of Maraviroc

PHASE3CompletedINTERVENTIONAL
Enrollment

209

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

September 30, 2010

Conditions
Acquired Immunodeficiency SyndromeHIV Infection
Interventions
DRUG

Maraviroc

Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.

Trial Locations (16)

14048900

Pfizer Investigational Site, Ribeirão Preto

40110-160

Pfizer Investigational Site, Salvador

70351-580

Pfizer Investigational Site, Brasília

30130-100

Pfizer Investigational Site, Belo Horizonte

80240-280

Pfizer Investigational Site, Curitiba

26030-380

Pfizer Investigational Site, Nova Iguaçu

90110-270

Pfizer Investigational Site, Porto Alegre

88025-301

Pfizer Investigational Site, Florianópolis

13059-900

Pfizer Investigational Site, Campinas

13083-887

Pfizer Investigational Site, Campinas

09060-650

Pfizer Investigational Site, Santo André

01246-900

Pfizer Investigational Site, São Paulo

01307-001

Pfizer Investigational Site, São Paulo

04040-002

Pfizer Investigational Site, São Paulo

04121-000

Pfizer Investigational Site, São Paulo

04231-030

Pfizer Investigational Site, São Paulo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

ViiV Healthcare

INDUSTRY